Literature DB >> 10366465

Results of primary and adjuvant radiotherapy in the treatment of mixed Müllerian tumors of the corpus uteri.

T H Knocke1, H D Weitmann, H Kucera, H Kölbl, B Pokrajac, R Pötter.   

Abstract

OBJECTIVE: The benefit of primary or adjuvant irradiation in the treatment of mixed Müllerian tumors is still not clear.
METHODS: During 1981-1997 63 patients were referred for primary (n = 13) or postoperative (n = 50) radiotherapy. Analysis of outcome of primarily and postoperatively irradiated patients was performed separately because of different staging systems. Of 50 patients treated after surgery 29 presented in histopathologic stage I, 4 in stage II, 14 in stage III, and 3 in stage IV. Clinical stage distribution for primary treatment was stage I: n = 9, stage II: n = 1, stage III: n = 3. Forty-four patients in the postoperatively treated group and 6 in the primarily treated group received radiotherapy with a curative intent; external beam therapy was given up to 56 Gy to the pelvis combined with intravaginal or intracavitary brachytherapy.
RESULTS: Five-year actuarial overall survival, disease-specific survival, local control, and distant control for 50 patients receiving adjuvant irradiation was 52.9, 57. 5, 83.4, and 70.8%, in stage I: 68.4, 76.1, 95.2, and 81.7%, in stage II: 50.0, 50.0, 75.0, and 66.7%, and in stage III: 31.3, 34.1%, 70.4, and 47.6%, respectively. Four of 13 patients treated with primary irradiation achieved long-term local control.
CONCLUSION: These data suggest that adjuvant radiotherapy improves local control and disease specific survival in the treatment of mixed Müllerian tumors compared to data in the literature concerning treatment by surgery alone. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10366465     DOI: 10.1006/gyno.1999.5400

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

Review 1.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

2.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

Review 3.  Uterine/female genital sarcomas.

Authors:  M L Hensley
Journal:  Curr Treat Options Oncol       Date:  2000-06

4.  A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Authors:  Elizabeth L Dickson; Rachel Isaksson Vogel; Paola A Gehrig; Stuart Pierce; Laura Havrilesky; Angeles Alvarez Secord; Joseph Dottino; Amanda N Fader; Stephanie Ricci; Melissa A Geller
Journal:  Gynecol Oncol       Date:  2015-09-06       Impact factor: 5.482

5.  Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).

Authors:  Jihye Cha; Young Seok Kim; Won Park; Hak Jae Kim; Joo Young Kim; Jin Hee Kim; Juree Kim; Won Sup Yoon; Jun Won Kim; Yong Bae Kim
Journal:  J Gynecol Oncol       Date:  2016-07-11       Impact factor: 4.401

6.  Uterine carcinosarcoma: A 10-year single institution experience.

Authors:  Leana Terblanche; Matthys H Botha
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.